ANP
- Category
- Cardiovascular
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A naturally occurring 28-amino-acid hormone used in hospitals to rapidly offload a failing heart in acute heart failure, not marketed for wellness or longevity. Its blood-pressure and pulmonary-pressure-lowering effects are well established in humans, but easing breathlessness is only weakly supported, and it has never shown a mortality benefit. The main danger is hypotension. It is a regulated acute-care infusion, not a research-grade peptide.
Read Full recordStudied uses & evidence
Studied uses(6)
Rapid reduction in pulmonary capillary wedge pressure in acute heart failure
HighPhase III RCT in 477 patients showed rapid drop in wedge pressure at 1 hour.
Improvement in dyspnea (breathlessness) in acutely decompensated CHF
SpeculativeLargest placebo-controlled RCT missed its dyspnea endpoint; symptom benefit remains unproven.
Vasodilation and blood pressure reduction through cGMP-mediated smooth muscle relaxation
HighBlood pressure lowering is well documented in human RCTs; hypotension is the dose-limiting effect.
Evidence limits
- Evidence Level
- Moderate
ANP has human trial evidence and carperitide has been approved in Japan since 1995. A 477-patient rhANP trial found transient pulmonary-pressure improvement without significant dyspnea or mortality benefit. VMAC and ASCEND-HF studied BNP/nesiritide and provide related-peptide evidence, not direct ANP evidence: nesiritide was FDA-approved in 2001 on the VMAC trial, and the ASCEND-HF trial (n=7141) showed no mortality benefit. BNP and NT-proBNP levels are guideline-recommended biomarkers for heart failure diagnosis.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
General cautions
Pregnancy or breastfeeding
AbsoluteNo human reproductive safety data exists for this peptide. Effects on fetal development are unknown.
Children under 18
AbsoluteNo pediatric safety data. Not recommended for use in minors.
Known hypersensitivity
AbsoluteDiscontinue immediately if allergic reaction occurs (rash, swelling, difficulty breathing).
Risk summary(4)
Risks = level of concern: High · Moderate · Low · Theoretical
Hypotension (dangerously low blood pressure)
HighWorsening renal function
ModerateNo mortality benefit despite hemodynamic effects
HighHeadache and nausea
Low
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.